{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-016724","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2026-05-13T20:10:24+00:00","discovered_at":"2026-05-13T20:11:00.402181+00:00","generated_at":"2026-05-13T22:05:22.601673+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Talphera Q1 net loss $2.6M; NEPHRO CRRT study enrollment progressing","bullets":["Net loss of $2.6M ($0.04 per share) in Q1 2026, flat vs Q1 2025.","Cash and investments $21.1M as of March 31, 2026.","Combined R&D and SG&A expenses $3.9M, up from $2.9M YoY due to higher Niyad development costs.","NEPHRO CRRT study enrollment exceeded 50% milestone; completion expected in 2026.","Closed $4.1M third tranche of private placement upon hitting 35-patient enrollment milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-016724","json":"https://secwatch.observer/filing/0001437749-26-016724.json","markdown":"https://secwatch.observer/filing/0001437749-26-016724.md","text":"https://secwatch.observer/filing/0001437749-26-016724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774926016724/0001437749-26-016724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774926016724/acrx20260511_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T22:05:22.601673+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}